Testosterone promotion lands drug co with $250k fine

Eli Lilly has been hit with a $250,000 fine after it used pharmacists to urge patients on testosterone replacement therapy to switch to the company’s own drug Axiron.

The strategy - apparently unknown to the company’s senior management -was adopted by one of its sales teams with the aim of getting patients to ask their GPs to change their existing treatment.

It was uncovered after a complaint by one of Eli Lilly’s own